Literature DB >> 17599933

Identification of aberrant chromosomal regions from gene expression microarray studies applied to human breast cancer.

Andreas Buness1, Ruprecht Kuner, Markus Ruschhaupt, Annemarie Poustka, Holger Sültmann, Achim Tresch.   

Abstract

MOTIVATION: In cancer, chromosomal imbalances like amplifications and deletions, or changes in epigenetic mechanisms like DNA methylation influence the transcriptional activity. These alterations are often not limited to a single gene but affect several genes of the genomic region and may be relevant for the disease status. For example, the ERBB2 amplicon (17q21) in breast cancer is associated with poor patient prognosis. We present a general, unsupervised method for genome-wide gene expression data to systematically detect tumor patients with chromosomal regions of distinct transcriptional activity. The method aims to find expression patterns of adjacent genes with a consistently decreased or increased level of gene expression in tumor samples. Such patterns have been found to be associated with chromosomal aberrations and clinical parameters like tumor grading and thus can be useful for risk stratification or therapy.
RESULTS: Our approach was applied to 12 independent human breast cancer microarray studies comprising 1422 tumor samples. We prioritized chromosomal regions and genes predominantly found across all studies. The result highlighted not only regions which are well known to be amplified like 17q21 and 11q13, but also others like 8q24 (distal to MYC) and 17q24-q25 which may harbor novel putative oncogenes. Since our approach can be applied to any microarray study it may become a valuable tool for the exploration of transcriptional changes in diverse disease types. AVAILABILITY: The R source codes which implement the method and an exemplary analysis are available at http://www.dkfz.de/mga2/people/buness/CTP/. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17599933     DOI: 10.1093/bioinformatics/btm340

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


  22 in total

1.  [Identification and validation of clinically relevant molecular alterations in prostate cancer].

Authors:  T Schlomm; H Sültmann; J Köllermann
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

2.  [Identification and validation of clinically relevant molecular alterations in prostate cancer].

Authors:  T Schlomm; H Sültmann; J Köllermann
Journal:  Pathologe       Date:  2009-03       Impact factor: 1.011

3.  Chromosome 8q24-Associated Cancers and MYC.

Authors:  Chiara Grisanzio; Matthew L Freedman
Journal:  Genes Cancer       Date:  2010-06

4.  C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

Authors:  Edith A Perez; Robert B Jenkins; Amylou C Dueck; Anne E Wiktor; Patrick P Bedroske; S Keith Anderson; Rhett P Ketterling; William R Sukov; Kazunori Kanehira; Beiyun Chen; Xochiquetzal J Geiger; Cathy A Andorfer; Ann E McCullough; Nancy E Davidson; Silvana Martino; George W Sledge; Peter A Kaufman; Leila A Kutteh; Julie R Gralow; Lyndsay N Harris; James N Ingle; Wilma L Lingle; Monica M Reinholz
Journal:  J Clin Oncol       Date:  2011-01-18       Impact factor: 44.544

5.  Sensitivity and resistance towards isoliquiritigenin, doxorubicin and methotrexate in T cell acute lymphoblastic leukaemia cell lines by pharmacogenomics.

Authors:  Mahmoud Youns; Yu-Jie Fu; Yuan-Gang Zu; Anne Kramer; V Badireenath Konkimalla; Bernhard Radlwimmer; Holger Sültmann; Thomas Efferth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-07-29       Impact factor: 3.000

6.  The B-type lamin is required for somatic repression of testis-specific gene clusters.

Authors:  Y Y Shevelyov; S A Lavrov; L M Mikhaylova; I D Nurminsky; R J Kulathinal; K S Egorova; Y M Rozovsky; D I Nurminsky
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-13       Impact factor: 11.205

7.  Multiple loci with different cancer specificities within the 8q24 gene desert.

Authors:  Maya Ghoussaini; Honglin Song; Thibaud Koessler; Ali Amin Al Olama; Zsofia Kote-Jarai; Kristy E Driver; Karen A Pooley; Susan J Ramus; Susanne Krüger Kjaer; Estrid Hogdall; Richard A DiCioccio; Alice S Whittemore; Simon A Gayther; Graham G Giles; Michelle Guy; Stephen M Edwards; Jonathan Morrison; Jenny L Donovan; Freddie C Hamdy; David P Dearnaley; Audrey T Ardern-Jones; Amanda L Hall; Lynne T O'Brien; Beatrice N Gehr-Swain; Rosemary A Wilkinson; Paul M Brown; John L Hopper; David E Neal; Paul D P Pharoah; Bruce A J Ponder; Rosalind A Eeles; Douglas F Easton; Alison M Dunning
Journal:  J Natl Cancer Inst       Date:  2008-06-24       Impact factor: 13.506

8.  Copy number increase of HER-2 in colorectal cancers.

Authors:  Yi Xiong; Zhengyu Fang; Chao Zhang; Guolong Qi; Wenli Liu; Wei Zhang; Jun Wan
Journal:  Oncol Lett       Date:  2010-12-08       Impact factor: 2.967

9.  Validation of UBE2C protein as a prognostic marker in node-positive breast cancer.

Authors:  D Loussouarn; L Campion; F Leclair; M Campone; C Charbonnel; G Ricolleau; W Gouraud; R Bataille; P Jézéquel
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

10.  Classification across gene expression microarray studies.

Authors:  Andreas Buness; Markus Ruschhaupt; Ruprecht Kuner; Achim Tresch
Journal:  BMC Bioinformatics       Date:  2009-12-30       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.